A Phase 2 interventional study of Acetaminophen/naproxen sodium Dose A and Acetaminophen/naproxen sodium Dose B in Pain, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Pain by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Pain · Johnson & Johnson.
Among the 104 studies in Pain by Johnson & Johnson, this one is the 32nd largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2020, is one of 14 in phase 2, and was the 100th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →None of the 104 studies in Pain by Johnson & Johnson is open now. The open studies under Pain, anywhere →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 17 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 41 · Phase 4 22
First in 1986; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 304 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 183 across the 88 interventional studies, 636 across the 15 observational. Of the 99 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 104 studies in Pain by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study assessing the relative efficacy of five strengths of a fixed combination of acetaminophen and naproxen sodium is being investigated to help inform selection of dose(s) for further development and to evaluate the safety of a fixed combination of naproxen sodium and acetaminophen.
This is a randomized, double-blind, placebo-controlled study to evaluate the analgesic efficacy and safety profile of the following doses of a fixed combination of Acetaminophen (APAP)/Naproxen sodium (NPX) administered as a single two-tablet dose:[Acetaminophen/Naproxen Sodium Dose A, Acetaminophen/Naproxen Sodium Dose B, Acetaminophen/Naproxen Sodium Dose C, Acetaminophen/Naproxen Sodium Dose D, Acetaminophen/Naproxen Sodium Dose E and Placebo] following surgical extraction of four third molars.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
Drug: Acetaminophen/naproxen sodium Dose A
Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
Drug: Acetaminophen/naproxen sodium Dose B
Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
Drug: Acetaminophen/naproxen sodium Dose C
Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
Drug: Acetaminophen/naproxen sodium Dose D
Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
Drug: Acetaminophen/naproxen sodium Dose E
Placebo tablets administered as a single two-tablet dose.
Drug: Placebo
Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
Placebo tablets administered as a single two-tablet dose.
Time Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)
Time weighted sum of the pain intensity difference (SPID) score is derived from pain intensity difference (PID) score. Pain intensity-numerical rating scale (PI-NRS) was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID score was the difference between baseline pain intensity and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the interval from 0 to 12 hours. The possible range of SPID for 0 to 12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief.
Time frame: Baseline (0 hour) up to 12 hours post-dose on Day 1
Time Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)
Time weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0 to10 (0 = no relief, 10 = complete relief). A higher score indicated greater pain relief. Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores were indicative of more pain relief.
Time frame: Baseline (0 hour) up to 12 hours post-dose on Day 1
Time Weighted Sum of Pain Intensity Difference Score From 6 Hours to 12 Hours (SPID 6-12)
Time weighted sum of the pain intensity difference (SPID) score is derived from PID score. PI-NRS was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID was the difference between pain intensity at 6 hours and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the intervals from 6 to 12 hours (6 hours). The possible range of SPID for 6 to12 hours was from -60 to 60. A higher value of SPID indicated greater pain relief.
Time frame: From 6 hours up to 12 hours post-dose on Day 1
Time to First Use of Rescue Analgesic Medication
Time to first use of rescue analgesic medication was measured as the elapsed time (in minutes) from when the investigational product was given until the time rescue analgesic was first given. Participants who did not use rescue medication during the 24 hour study period had their time to rescue set to 24 hours and were censored at 24 hours. Kaplan-Meier method was used for the analysis.
Time frame: From 0 minute up to 1440 minutes post-dose (that is, up to 24 hours post-dose) on Day 1
Proportion of Participants Who Required Rescue Analgesic Medication
Proportion (cumulative data) of participants who used rescue analgesic medication through 24 hours post study drug administration on Day 1 which was assessed by using Kaplan-Meier estimates were reported.
Time frame: From 0 hour up to 24 hours post-dose on Day 1
| Milestone | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| Started | 53 | 49 | 53 | 52 | 51 | 46 |
| Completed | 51 | 47 | 49 | 48 | 50 | 43 |
| Not completed | 2 | 2 | 4 | 4 | 1 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 | 3 | 3 | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 0 | 0 |
Time weighted sum of the pain intensity difference (SPID) score is derived from pain intensity difference (PID) score. Pain intensity-numerical rating scale (PI-NRS) was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID score was the difference between baseline pain intensity and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the interval from 0 to 12 hours. The possible range of SPID for 0 to 12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief.
| Units on a scale | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| Time Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12) | 5.59 ± 3.741 | 37.08 ± 3.892 | 46.98 ± 3.740 | 52.45 ± 3.779 | 59.63 ± 3.813 | 65.52 ± 4.027 |
Time weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0 to10 (0 = no relief, 10 = complete relief). A higher score indicated greater pain relief. Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores were indicative of more pain relief.
| Units on a scale | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| Time Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12) | 18.40 ± 4.550 | 54.06 ± 4.734 | 67.45 ± 4.548 | 72.04 ± 4.597 | 79.33 ± 4.637 | 85.98 ± 4.898 |
Time weighted sum of the pain intensity difference (SPID) score is derived from PID score. PI-NRS was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID was the difference between pain intensity at 6 hours and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the intervals from 6 to 12 hours (6 hours). The possible range of SPID for 6 to12 hours was from -60 to 60. A higher value of SPID indicated greater pain relief.
| Units on a scale | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| Time Weighted Sum of Pain Intensity Difference Score From 6 Hours to 12 Hours (SPID 6-12) | 2.58 ± 2.154 | 15.12 ± 2.241 | 20.31 ± 2.153 | 24.47 ± 2.176 | 27.59 ± 2.195 | 31.89 ± 2.318 |
Time to first use of rescue analgesic medication was measured as the elapsed time (in minutes) from when the investigational product was given until the time rescue analgesic was first given. Participants who did not use rescue medication during the 24 hour study period had their time to rescue set to 24 hours and were censored at 24 hours. Kaplan-Meier method was used for the analysis.
| Minutes | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| Time to First Use of Rescue Analgesic Medication | 90.0 (38 to 1440) | 898.0 (33 to 1440) | 1195.0 (30 to 1440) | NA (0 to 1440) | NA (68 to 1440) | NA (497 to 1440) |
Proportion (cumulative data) of participants who used rescue analgesic medication through 24 hours post study drug administration on Day 1 which was assessed by using Kaplan-Meier estimates were reported.
| Proportion of participants | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| Proportion of Participants Who Required Rescue Analgesic Medication | 0.792 (0.675 to 0.889) | 0.571 (0.439 to 0.711) | 0.519 (0.392 to 0.659) | 0.353 (0.239 to 0.500) | 0.353 (0.239 to 0.500) | 0.152 (0.076 to 0.293) |
Collected over From baseline (Day 1; day of surgery) up to Day 10. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/53 (0%) | 0/53 (0%) | 12/53 (22.6%) |
| Acetaminophen/Naproxen Sodium Dose A | 0/49 (0%) | 0/49 (0%) | 7/49 (14.3%) |
| Acetaminophen/Naproxen Sodium Dose B | 0/53 (0%) | 0/53 (0%) | 6/53 (11.3%) |
| Acetaminophen/Naproxen Sodium Dose C | 0/52 (0%) | 0/52 (0%) | 5/52 (9.6%) |
| Acetaminophen/Naproxen Sodium Dose D | 0/51 (0%) | 0/51 (0%) | 3/51 (5.9%) |
| Acetaminophen/Naproxen Sodium Dose E | 0/46 (0%) | 0/46 (0%) | 3/46 (6.5%) |
| Event | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/53 | 5/49 | 2/53 | 2/52 | 2/51 | 1/46 |
| VomitingGastrointestinal disorders | 6/53 | 1/49 | 2/53 | 0/52 | 1/51 | 0/46 |
| HeadacheNervous system disorders | 1/53 | 1/49 | 1/53 | 0/52 | 0/51 | 2/46 |
| DizzinessNervous system disorders | 0/53 | 1/49 | 0/53 | 0/52 | 1/51 | 0/46 |
| HaemorrhageVascular disorders | 0/53 | 1/49 | 0/53 | 1/52 | 0/51 | 0/46 |
| BronchitisInfections and infestations | 0/53 | 0/49 | 0/53 | 0/52 | 1/51 | 0/46 |
| RashSkin and subcutaneous tissue disorders | 0/53 | 0/49 | 0/53 | 0/52 | 1/51 | 0/46 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/53 | 0/49 | 0/53 | 1/52 | 0/51 | 0/46 |
| PyrexiaGeneral disorders | 0/53 | 0/49 | 0/53 | 1/52 | 0/51 | 0/46 |
| Alveolar osteitisInfections and infestations | 0/53 | 0/49 | 1/53 | 0/52 | 0/51 | 0/46 |
| Age, Continuous(Years) | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E | Total |
|---|---|---|---|---|---|---|---|
| Mean | 18.5 ± 1.78 | 18.4 ± 1.83 | 18.6 ± 2.05 | 18.7 ± 1.95 | 18.5 ± 1.82 | 18.2 ± 1.50 | 18.5 ± 1.83 |
| Sex: Female, Male(Participants) | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E | Total |
|---|---|---|---|---|---|---|---|
| Female | 25 | 27 | 26 | 25 | 27 | 24 | 154 |
| Male | 28 | 22 | 27 | 27 | 24 | 22 | 150 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 6 | 5 | 2 | 2 | 9 | 36 |
| Not Hispanic or Latino | 40 | 43 | 48 | 50 | 49 | 37 | 267 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Acetaminophen/Naproxen Sodium Dose A | Acetaminophen/Naproxen Sodium Dose B | Acetaminophen/Naproxen Sodium Dose C | Acetaminophen/Naproxen Sodium Dose D | Acetaminophen/Naproxen Sodium Dose E | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 1 | 1 | 2 | 1 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 1 | 0 | 0 | 3 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 50 | 48 | 51 | 48 | 50 | 45 | 292 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Data sharing details ↗ · yoda.yale.edu.
Ran from Nov 2020 to primary completion in Apr 2021, 5 months.
Results were first posted in Apr 2024, 3 years after primary completion. A results delay was requested in Apr 2022.
Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division →